← 홈

다발성 골수종

229개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 229개
AntibodySHOTFDACuratedFDABiologicJanssenApproved

daratumumab (Darzalex)

Multiple myeloma · CD38

#CD38#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 97%임상시험 440상태 APPROVED
ADCAHOTFDACuratedFDABiologicGSKMMAFApproved

belantamab mafodotin (Blenrep, GSK2857916)

Multiple myeloma · BCMA

#BCMA#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 57%임상시험 76상태 DISCONTINUED
AntibodyAHotRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#인기#항체+5
효능 ORR 95%임상시험 141상태 RECRUITING
CGTCHotBiologicstaleThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 113상태 DISCONTINUED
AntibodyCstaleJanssenPhase 2

Tec (Teclistamab, Teclistamab (Tec))

AL Amyloidosis · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#인기#항체+4
임상시험 88상태 RECRUITING
ADCCBiologicChristopher StrousePhase 2

Sirolimus (Sirolimus)

Multiple Myeloma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 9%임상시험 81상태 DISCONTINUED
CGTABiologicNational Cancer Institute (NCI)inPhase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 73상태 RECRUITING
ADCBBiologicMerck Sharp & Dohme LLCPhase 2

Cytoxan (Cytoxan)

Multiple Myeloma, Refractory · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 95%임상시험 73상태 RECRUITING
ADCBBiologicPalleos Healthcare GmbHvedotin, vinblastine, and d…Phase 2

Adriamycin (Adriamycin)

Multiple Myeloma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 95%임상시험 70상태 ACTIVE
ADCABiologicstaleGSKcys-mcMMAFPhase 3

belantamab mafodotin (Blenrep, GSK2857916)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 100%임상시험 69상태 RECRUITING
AntibodyGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 64상태 ACTIVE
ADCBiologicK36 Therapeutics, Inc.Phase 2

Dexamethasone oral (Dexamethasone oral)

Multiple Myeloma · Breast Neoplasms

#BreastNeoplasms#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 90%임상시험 62상태 RECRUITING
ADCBiologicCelyad Oncology SAPhase 2

Endoxan (Endoxan)

Relapse/Refractory Multiple Myeloma · Lymphoma, T-Cell, Peripheral

#LymphomaT-CellPeripheral#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 95%임상시험 62상태 ACTIVE
CGTBiologicMalaysia Palm Oil BoardPhase 1

Interleukin (Interleukin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#인기#세포유전치료+3
효능 ORR 2%임상시험 60상태 ACTIVE
AntibodyJanssenApproved

Teclistamab (Teclistamab)

Myeloma Multiple; Plasma Cell Leukemia · Myeloma Multiple

#MyelomaMultiple#Antibody#Approved#인기#항체+5
임상시험 60상태 RECRUITING
CGTBiologicCelgenevedotin (BV) maintenance th…Phase 2

ASCT (ASCT)

Multiple Myeloma; Newly Diagnosed · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#인기#세포유전치료+5
효능 ORR 11%임상시험 59상태 RECRUITING
ADCBiologicKaryopharm Therapeutics IncPhase 2

Clarithromycin (Clarithromycin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 6%임상시험 59상태 RECRUITING
ADCBiologicAmerican Society of Clinical On…Phase 2

Dabrafenib plus Trametinib (Dabrafenib plus Trametinib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 100%임상시험 57상태 RECRUITING
AntibodyPfizerPhase 3

Elotuzumab (Elotuzumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+4
효능 ORR 100%임상시험 57상태 RECRUITING
CGTBiologicMinsk Scientific-Practical Cent…Phase 2

Anti-BCMA CAR-T cells (Anti-BCMA CAR-T cells)

Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#인기#세포유전치료+5
효능 ORR 97.1%임상시험 56상태 RECRUITING

1 / 12 페이지

← 이전다음 →